| 4.0099 -0.014 (-0.35%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.65 |
1-year : | 4.87 |
| Resists | First : | 3.98 |
Second : | 4.17 |
| Pivot price | 3.93 |
|||
| Supports | First : | 3.67 |
Second : | 3.05 |
| MAs | MA(5) : | 4 |
MA(20) : | 3.93  |
| MA(100) : | 4.23 |
MA(250) : | 4.08 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.4 |
D(3) : | 66.6 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 5.36 | Low : | 3.41 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MOLN ] has closed above bottom band by 13.4%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.01 - 4.03 | 4.03 - 4.05 |
| Low: | 3.73 - 3.76 | 3.76 - 3.78 |
| Close: | 3.75 - 3.78 | 3.78 - 3.82 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Thu, 09 Jul 2026
MOLN Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 07 Jul 2026
Molecular Partners (MOLN) Gains 2.25% as Buyers Test Resistance Near $4.29 - AD Line Divergence - dars.gov.et
Tue, 07 Jul 2026
Molecular Partners (NASDAQ: MOLN) details progress in Radio-DARPin cancer pipeline - Stock Titan
Mon, 06 Jul 2026
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com - Investing.com South Africa
Thu, 02 Jul 2026
Molecular Partners (MOLN) starts first patient dosing in DLL3 Radio-DARPin MP0712 Phase 1/2a - Stock Titan
Wed, 01 Jul 2026
MOLN Q4 2025 Earnings: Narrower-Than-Expected Loss as Biotech Advances Pipeline - Annual Report - dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.5 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -59.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.98 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -1.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|